Literature DB >> 21671360

Magnetic resonance imaging in childhood leukemia survivors treated with cranial radiotherapy: a cross sectional, single center study.

Maura Faraci1, Giovanni Morana, Francesca Bagnasco, Salvina Barra, Paola Polo, Guia Hanau, Francesca Fioredda, Silvia Caruso, Andrea Rossi, Renato Spaziante, Riccardo Haupt.   

Abstract

BACKGROUND: Children treated with cranial radiotherapy (CRT) for leukemia are at risk of developing central nervous system injuries. Magnetic resonance imaging (MRI) represents the examination method of choice for evaluating radiation-induced brain complications. The purpose of this report is to describe the spectrum of MRI abnormalities detected in a group of survivors of leukemia treated with cranial irradiation. PROCEDURES: In this cross-sectional, single center study, 56 patients (median age at follow-up 19 years) receiving CRT as cranial prophylaxis (CP) included in the leukemia protocol (total dose 1,800-2,400 cGy) and/or in the total body irradiation regimen (990-1,200 cGy) before hematopoietic stem cell transplant, were evaluated by MRI after a median interval of 11 years (range 2-27) following CRT.
RESULTS: Fifty-nine MRI abnormalities (32 cavernomas, nine focal areas of gliosis, seven dystrophic mineralizations, five cerebral atrophies, four pituitary atrophies, one diffuse radiation leukoencephalopathy, and one meningioma) were found in 43 patients. The longest interval between CRT and MRI and oldest age at follow-up represented the two risk factors that were statistically associated with MRI lesions (P = 0.032 and 0.033, respectively). Cerebral cavernomas (CC) were the most frequent MRI abnormalities (57%). All patients with CC were asymptomatic at diagnosis and during follow-up, except one who had aspecific neurological manifestations and micro hemorrhages.
CONCLUSIONS: These results confirm that total doses and modalities of fractionation dose of CRT were not significantly associated with MRI abnormalities. Moreover, in our experience none of the patients developed neurological symptoms related to MRI abnormalities, and furthermore, the CC remained substantially stable during follow-up.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21671360     DOI: 10.1002/pbc.22923

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients.

Authors:  Erica Gastelum; Katherine Sear; Nancy Hills; Erika Roddy; Dominica Randazzo; Nassim Chettout; Christopher Hess; Jennifer Cotter; Daphne A Haas-Kogan; Heather Fullerton; Sabine Mueller
Journal:  J Child Neurol       Date:  2014-08-13       Impact factor: 1.987

2.  Aberrant paramagnetic signals outside the tumor volume on routine surveillance MRI of brain tumor patients.

Authors:  Shlomit Yust-Katz; Edna Inbar; Natalia Michaeli; Dror Limon; Tali Siegal
Journal:  J Neurooncol       Date:  2017-07-10       Impact factor: 4.130

Review 3.  Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature.

Authors:  Maria Camilla Rossi Espagnet; Luca Pasquini; Antonio Napolitano; Antonella Cacchione; Angela Mastronuzzi; Roberta Caruso; Paolo Tomà; Daniela Longo
Journal:  Pediatr Radiol       Date:  2016-12-09

4.  Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

Authors:  D Bresters; A Lawitschka; C Cugno; U Pötschger; A Dalissier; G Michel; K Vettenranta; M Sundin; A Al-Seraihy; M Faraci; P Sedlacek; A B Versluys; A Jenkins; P Lutz; B Gibson; A Leiper; M A Diaz; P J Shaw; R Skinner; T A O'Brien; N Salooja; P Bader; C Peters
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

5.  Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy.

Authors:  Angela Di Giannatale; Giovanni Morana; Andrea Rossi; Armando Cama; Luisella Bertoluzzo; Salvina Barra; Paolo Nozza; Claudia Milanaccio; Alessandro Consales; Maria Luisa Garrè
Journal:  J Neurooncol       Date:  2014-02-11       Impact factor: 4.130

6.  Radiation Associated Meningiomas:The Case for Repeat Radiotherapy.

Authors:  Robert I Smee
Journal:  J Radiosurg SBRT       Date:  2011

Review 7.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel.

Authors:  Amy Akers; Rustam Al-Shahi Salman; Issam A Awad; Kristen Dahlem; Kelly Flemming; Blaine Hart; Helen Kim; Ignacio Jusue-Torres; Douglas Kondziolka; Cornelia Lee; Leslie Morrison; Daniele Rigamonti; Tania Rebeiz; Elisabeth Tournier-Lasserve; Darrel Waggoner; Kevin Whitehead
Journal:  Neurosurgery       Date:  2017-05-01       Impact factor: 4.654

8.  Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia.

Authors:  Julia Walch; Barbara Tettenborn; Johannes Weber; Thomas Hundsberger
Journal:  Case Rep Neurol       Date:  2013-04-18

9.  Pathological Evaluation of Radiation-Induced Vascular Lesions of the Brain: Distinct from De Novo Cavernous Hemangioma.

Authors:  Yoon Jin Cha; Ji Hae Nahm; Ji Eun Ko; Hyun Joo Shin; Jong-Hee Chang; Nam Hoon Cho; Se Hoon Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

10.  Cerebral microbleeds in adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation.

Authors:  Nicholas S Phillips; Claudia M Hillenbrand; Bogdan G Mitrea; Jason Yan; Chenghong Li; Matthew A Scoggins; Thomas E Merchant; Gregory T Armstrong; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kevin R Krull; Noah D Sabin
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.